Avacta Says Non-Executive Director Michael Albin To Stand Down Friday

LONDON (Alliance News) - Avacta Group PLC, a healthcare products company that specialises in Affimer products that bind molecules together, said Thursday that non-executive director Michael Albin will be stepping down from the board effective from Friday.

Albin has 30 years experience in the development and global commercialisation of technologies for the life sciences. Including roles as scientific advisor of Stratos Product Development LLC, vice president for strategic technologies for Applera Corp and as principal scientist at Applied Biosystems.

Albin was granted USD6 million from the National Institute of Standards and Technology for a technology he developed for Applied Biosystems for micro-volume polymerase chain reaction that has been patented and commercialised.

Avacta Chief Executive Officer Alastair Smith said: "I would like to thank Michael for his contribution to the group over the last four years, his advice and support around the development of our Affimer technology has been invaluable. I am glad that Michael's association with Avacta will continue in an advisory capacity."

Shares in Avacta were trading at 35.10 pence, down 1.1%, Thursday afternoon.